Mixed Connective Tissue Disease (MCTD) Clinical Trials

Mixed connective tissue disease (MCTD) is a rare systemic autoimmune disorder characterized by high titers of anti-RNP (anti-ribonucleoprotein) antibodies and clinical features overlapping systemic lupus erythematosus (SLE), systemic sclerosis, and polymyositis, occurring in a distinct pattern not fully meeting criteria for any single connective tissue disease. The disease manifests with Raynaud phenomenon in nearly all patients, often the presenting symptom, followed by hand edema, polyarthralgias, and myalgia. Progressive sclerosis of skin occurs, particularly affecting hands and forearms (sclerodactyly), developing in most patients over time.

The most common symptoms of Mixed Connective Tissue Disease include Raynaud phenomenon, Hand edema and sclerodactyly, Myalgia and arthritis, Photosensitivity and rashes, Dysphagia and esophageal dysfunction, among others. Mixed Connective Tissue Disease affects approximately 1 in 100,000 to 200,000 people. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Mixed Connective Tissue Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Clinical trials are investigating immunosuppressive agents and targeted biologic therapies for MCTD-related organ dysfunction, particularly pulmonary hypertension and fibrosis. Pulmonary function testing and echocardiography screening detect early pulmonary involvement, enabling intervention with vasodilators, immunosuppression, or other agents before functional decline.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Mixed Connective Tissue Disease. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

The exact cause of Mixed Connective Tissue Disease is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Defined by anti-U1-RNP autoantibodies; immune-regulatory genes influence risk but there is no diagnostic gene test. The condition affects approximately 1 in 100,000 to 200,000 people. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Mixed Connective Tissue Disease. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Defined by anti-U1-RNP autoantibodies; immune-regulatory genes influence risk but there is no diagnostic gene test.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Mixed Connective Tissue Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Mixed Connective Tissue Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.